| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.32 | 0.1 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.071 | 0.1 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.1 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.089 | 0.1 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | AZD-2281 | FIMM | pan-cancer | AAC | 0.3 | 0.1 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |